PMID- 19582880
OWN - NLM
STAT- MEDLINE
DCOM- 20090921
LR  - 20220318
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 125
IP  - 8
DP  - 2009 Oct 15
TI  - Expression of the macrophage antigen CD163 in rectal cancer cells is associated 
      with early local recurrence and reduced survival time.
PG  - 1826-31
LID - 10.1002/ijc.24506 [doi]
AB  - Expression of the macrophage antigen CD163 in breast cancer cells is recently 
      shown to be related to early distant recurrence and shortened survival. In this 
      study, 163 patients with rectal cancer, included in the Swedish rectal cancer 
      trial and followed up for a median of 71 months, were examined for the expression 
      of CD163 in the primary tumors. The cancer cells expressed CD163 in the primary 
      tumors in 23% (n = 32) of the patients. In pretreatment biopsies from 101 
      patients, 10 had CD163-positive cancers and these patients had earlier local 
      recurrence (p < 0.044) and reduced survival time (p < 0.045) compared with those 
      with CD163-negative tumors. When studying surgical specimens from 61 patients 
      randomized to preoperative irradiation (5 x 5 Gy delivered in 1 week), it was 
      found that 31% were CD163 positive whereas the corresponding figure was only 17% 
      for 78 patients who were nonirradiated (p < 0.044), which tentatively may be 
      consistent with X-rays inducing fusion. In CD163-positive tumors there was a 
      reduced apoptotic activity as measured with the Termina deoxynucleotidyl 
      Transferase Biotin-dUTP Nick End Labeling (TUNEL) technique (p = 0.018). There 
      tended also to be an increased proliferation activity measured as an expression 
      of Ki-67 non significant (NS). It is concluded that primary rectal cancers may 
      express CD-163, and this phenotypic macrophage trait is related to early local 
      recurrence, shorter survival time and reduced apoptosis. Furthermore, the 
      expression of CD163 is more common after irradiation.
FAU - Shabo, Ivan
AU  - Shabo I
AD  - Division of Surgery, Institution of Clinical and Experimental Medicine, 
      University of Linkoping, Sweden.
FAU - Olsson, Hans
AU  - Olsson H
FAU - Sun, Xiao-Feng
AU  - Sun XF
FAU - Svanvik, Joar
AU  - Svanvik J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD163 antigen)
RN  - 0 (Receptors, Cell Surface)
SB  - IM
MH  - Aged
MH  - Antigens, CD/*metabolism
MH  - Antigens, Differentiation, Myelomonocytic/*metabolism
MH  - Apoptosis
MH  - Biomarkers, Tumor/*metabolism
MH  - Case-Control Studies
MH  - Cell Proliferation
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Macrophages/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*metabolism/mortality/therapy
MH  - Neoplasm Staging
MH  - Preoperative Care
MH  - Prognosis
MH  - Radiotherapy Dosage
MH  - Receptors, Cell Surface/*metabolism
MH  - Rectal Neoplasms/*metabolism/mortality/therapy
MH  - Survival Rate
MH  - Tissue Array Analysis
EDAT- 2009/07/08 09:00
MHDA- 2009/09/22 06:00
CRDT- 2009/07/08 09:00
PHST- 2009/07/08 09:00 [entrez]
PHST- 2009/07/08 09:00 [pubmed]
PHST- 2009/09/22 06:00 [medline]
AID - 10.1002/ijc.24506 [doi]
PST - ppublish
SO  - Int J Cancer. 2009 Oct 15;125(8):1826-31. doi: 10.1002/ijc.24506.